What's Happening

A biosimilar to Stelara, this drug is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderate to severe ulcerative colitis

An opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose induced by natural or synthetic opioids.

Indicated for the emergency treatment of type I allergic reactions, including anaphylaxis

Indicated for the treatment of hypertension alone or with other antihypertensive agents, and for the treatment of enlarged prostate

Indicated for the treatment of mild to moderate dementia of the Alzheimer's type

Indicated for the treatment of moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers

Indicated for the treatment of Alzheimer's disease. Treatment with Kisunla should be initiated in patient with mild cognitive impairment or mild dementia stage of disease, the population in which the treatment was initiated in the clinical trials

Indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management

Indicated for the treatment of erectile dysfunction

A biosimilar to Stelara; indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis